Riskpilot← Back to searchSign inGet full accessBiovica Services AB
ABActiveOrg 5567818454Dag Hammarskjölds Väg 54 BManufacture of medical and dental instruments and supplies · NACE 3250Est. 20090 employees
Revenue 2025
SEK 0
EBITDA margin
—
-15% vs 2024
Equity ratio
96.3%
Financial strength
Net profit 2025
SEK -30K
-25% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -31K | -15% |
| Net profit | SEK -30K | -25% |
| Total assets | SEK 355K | -10% |
| Equity | SEK 342K | -8% |
| Employees | 0 | — |
Legal name
Biovica Services AB
Org number
5567818454
Legal form
Aktiebolag
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
4 maj 2009
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning, utveckling, tillverkning, marknadsföring och försäljning av produkter för uppföljning och behandling av sjukdomar, främst inom tumör och virusområdet.
Address
Dag Hammarskjölds Väg 54 B
Email
info@biovica.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 147 | 1 055 | −53 | −27 | −31 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 1 147 | 1 055 | −53 | −27 | −31 |
| Net financials | — | −1 | 1 | 2 | 2 |
| Profit before tax | 0 | 0 | −52 | −24 | −30 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | 0 | −52 | −24 | −30 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 609 | 2 672 | 421 | 396 | 355 |
| Equity | 448 | 448 | 396 | 371 | 342 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 161 | 2 224 | 25 | 25 | 14 |
| Total debt | 1 161 | 2 224 | 25 | 25 | 14 |
EBITDA margin
-3100000.0%
This company
15.8%
Market median
-19620353% vs market
20212025
Equity ratio
96.3%
This company
38.2%
Market median
+152% vs market
20212025
Return on equity
-8.8%
This company
18.4%
Market median
-148% vs market
20212025
Net profit margin
-3000000.0%
This company
8.1%
Market median
-37037137% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SA Chief Auditor | Chief Auditor | 2022 |
PA Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Biovica International AB
Biovica Services AB Board members of Biovica Services AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stéphanie Anna Chantal Ljungberg | Chief Auditor | 0 companies |
| Per Anders Bernhard Rylander | Chief Executive Officer | 0 companies |
| Karl Frans Anders Morén | Board of Directors | 0 companies |
| Lars Erik Holmqvist | Chairman | 0 companies |